Go Pro
→ CODE RED: AI Meltdown Imminent? (From Paradigm Press) (Ad)tc pixel Free QUCY Stock Alerts

Mainz Biomed (QUCY) Competitors

$1.16 +0.01 (+0.43%)
As of 11:58 AM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare

QUCY vs. LFVN, HRTX, GANX, AIFC, and TLPH

Should you buy Mainz Biomed stock or one of its competitors? MarketBeat compares Mainz Biomed with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Mainz Biomed include Lifevantage (LFVN), Heron Therapeutics (HRTX), Gain Therapeutics (GANX), ALT5 Sigma (AIFC), and Talphera (TLPH). These companies are all part of the "pharmaceutical products" industry.

How does Mainz Biomed compare to Lifevantage?

Lifevantage (NASDAQ:LFVN) and Mainz Biomed (NASDAQ:QUCY) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, risk, earnings, dividends and media sentiment.

In the previous week, Mainz Biomed had 3 more articles in the media than Lifevantage. MarketBeat recorded 4 mentions for Mainz Biomed and 1 mentions for Lifevantage. Lifevantage's average media sentiment score of 1.05 beat Mainz Biomed's score of 0.25 indicating that Lifevantage is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Lifevantage
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Mainz Biomed
0 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

35.3% of Lifevantage shares are owned by institutional investors. 22.0% of Lifevantage shares are owned by insiders. Comparatively, 3.1% of Mainz Biomed shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Lifevantage currently has a consensus target price of $5.00, indicating a potential downside of 19.61%. Given Lifevantage's stronger consensus rating and higher possible upside, analysts plainly believe Lifevantage is more favorable than Mainz Biomed.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lifevantage
0 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
Mainz Biomed
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50

Lifevantage has a net margin of 2.94% compared to Mainz Biomed's net margin of 0.00%. Lifevantage's return on equity of 23.89% beat Mainz Biomed's return on equity.

Company Net Margins Return on Equity Return on Assets
Lifevantage2.94% 23.89% 12.47%
Mainz Biomed N/A N/A N/A

Lifevantage has a beta of 0.73, indicating that its stock price is 27% less volatile than the broader market. Comparatively, Mainz Biomed has a beta of 2.28, indicating that its stock price is 128% more volatile than the broader market.

Lifevantage has higher revenue and earnings than Mainz Biomed. Mainz Biomed is trading at a lower price-to-earnings ratio than Lifevantage, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lifevantage$228.53M0.34$9.81M$0.4513.82
Mainz Biomed$540K31.63-$16.21M-$47.60N/A

Summary

Lifevantage beats Mainz Biomed on 12 of the 15 factors compared between the two stocks.

How does Mainz Biomed compare to Heron Therapeutics?

Heron Therapeutics (NASDAQ:HRTX) and Mainz Biomed (NASDAQ:QUCY) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, valuation, earnings, media sentiment and risk.

Heron Therapeutics has a beta of 1.65, suggesting that its stock price is 65% more volatile than the broader market. Comparatively, Mainz Biomed has a beta of 2.28, suggesting that its stock price is 128% more volatile than the broader market.

Mainz Biomed has a net margin of 0.00% compared to Heron Therapeutics' net margin of -20.53%. Mainz Biomed's return on equity of 0.00% beat Heron Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Heron Therapeutics-20.53% -7,747.30% -8.94%
Mainz Biomed N/A N/A N/A

In the previous week, Mainz Biomed had 4 more articles in the media than Heron Therapeutics. MarketBeat recorded 4 mentions for Mainz Biomed and 0 mentions for Heron Therapeutics. Mainz Biomed's average media sentiment score of 0.25 beat Heron Therapeutics' score of -1.00 indicating that Mainz Biomed is being referred to more favorably in the news media.

Company Overall Sentiment
Heron Therapeutics Negative
Mainz Biomed Neutral

80.0% of Heron Therapeutics shares are owned by institutional investors. 6.1% of Heron Therapeutics shares are owned by company insiders. Comparatively, 3.1% of Mainz Biomed shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Mainz Biomed has lower revenue, but higher earnings than Heron Therapeutics. Heron Therapeutics is trading at a lower price-to-earnings ratio than Mainz Biomed, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Heron Therapeutics$154.90M0.58-$20.19M-$0.18N/A
Mainz Biomed$540K31.63-$16.21M-$47.60N/A

Heron Therapeutics presently has a consensus target price of $2.50, suggesting a potential upside of 423.01%. Given Heron Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Heron Therapeutics is more favorable than Mainz Biomed.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Heron Therapeutics
2 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.00
Mainz Biomed
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50

Summary

Mainz Biomed beats Heron Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Mainz Biomed compare to Gain Therapeutics?

Gain Therapeutics (NASDAQ:GANX) and Mainz Biomed (NASDAQ:QUCY) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, analyst recommendations, institutional ownership, risk, earnings, valuation and dividends.

12.0% of Gain Therapeutics shares are held by institutional investors. 4.2% of Gain Therapeutics shares are held by insiders. Comparatively, 3.1% of Mainz Biomed shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Mainz Biomed's return on equity of 0.00% beat Gain Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Gain TherapeuticsN/A -201.44% -136.24%
Mainz Biomed N/A N/A N/A

Mainz Biomed has higher revenue and earnings than Gain Therapeutics. Gain Therapeutics is trading at a lower price-to-earnings ratio than Mainz Biomed, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gain Therapeutics$50K1,479.96-$20.16M-$0.58N/A
Mainz Biomed$540K31.63-$16.21M-$47.60N/A

Gain Therapeutics has a beta of 0.15, indicating that its stock price is 85% less volatile than the broader market. Comparatively, Mainz Biomed has a beta of 2.28, indicating that its stock price is 128% more volatile than the broader market.

Gain Therapeutics currently has a consensus target price of $7.50, suggesting a potential upside of 332.28%. Given Gain Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Gain Therapeutics is more favorable than Mainz Biomed.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Gain Therapeutics
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.67
Mainz Biomed
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50

In the previous week, Mainz Biomed had 1 more articles in the media than Gain Therapeutics. MarketBeat recorded 4 mentions for Mainz Biomed and 3 mentions for Gain Therapeutics. Mainz Biomed's average media sentiment score of 0.25 beat Gain Therapeutics' score of 0.00 indicating that Mainz Biomed is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Gain Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Mainz Biomed
0 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Mainz Biomed beats Gain Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Mainz Biomed compare to ALT5 Sigma?

Mainz Biomed (NASDAQ:QUCY) and ALT5 Sigma (NASDAQ:AIFC) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, media sentiment, dividends, valuation, risk, profitability and institutional ownership.

Mainz Biomed has a beta of 2.28, meaning that its stock price is 128% more volatile than the broader market. Comparatively, ALT5 Sigma has a beta of 1.75, meaning that its stock price is 75% more volatile than the broader market.

6.3% of ALT5 Sigma shares are held by institutional investors. 3.1% of Mainz Biomed shares are held by insiders. Comparatively, 0.2% of ALT5 Sigma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Mainz Biomed has higher earnings, but lower revenue than ALT5 Sigma.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mainz Biomed$540K31.63-$16.21M-$47.60N/A
ALT5 Sigma$24.84M3.07-$344.51MN/AN/A

In the previous week, Mainz Biomed had 3 more articles in the media than ALT5 Sigma. MarketBeat recorded 4 mentions for Mainz Biomed and 1 mentions for ALT5 Sigma. Mainz Biomed's average media sentiment score of 0.25 beat ALT5 Sigma's score of 0.00 indicating that Mainz Biomed is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Mainz Biomed
0 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
ALT5 Sigma
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Mainz Biomed has a net margin of 0.00% compared to ALT5 Sigma's net margin of -2,483.94%. Mainz Biomed's return on equity of 0.00% beat ALT5 Sigma's return on equity.

Company Net Margins Return on Equity Return on Assets
Mainz BiomedN/A N/A N/A
ALT5 Sigma -2,483.94%-68.25%-62.43%

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Mainz Biomed
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50
ALT5 Sigma
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

Mainz Biomed beats ALT5 Sigma on 10 of the 12 factors compared between the two stocks.

How does Mainz Biomed compare to Talphera?

Mainz Biomed (NASDAQ:QUCY) and Talphera (NASDAQ:TLPH) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, profitability, earnings, dividends, media sentiment, valuation, risk and analyst recommendations.

Mainz Biomed has a beta of 2.28, suggesting that its stock price is 128% more volatile than the broader market. Comparatively, Talphera has a beta of 0.7, suggesting that its stock price is 30% less volatile than the broader market.

Mainz Biomed's return on equity of 0.00% beat Talphera's return on equity.

Company Net Margins Return on Equity Return on Assets
Mainz BiomedN/A N/A N/A
Talphera N/A -92.98%-53.22%

37.7% of Talphera shares are owned by institutional investors. 3.1% of Mainz Biomed shares are owned by company insiders. Comparatively, 3.5% of Talphera shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Talphera has a consensus target price of $3.00, indicating a potential upside of 131.30%. Given Talphera's stronger consensus rating and higher possible upside, analysts plainly believe Talphera is more favorable than Mainz Biomed.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Mainz Biomed
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50
Talphera
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25

Talphera has lower revenue, but higher earnings than Mainz Biomed. Talphera is trading at a lower price-to-earnings ratio than Mainz Biomed, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mainz Biomed$540K31.63-$16.21M-$47.60N/A
Talphera$30K2,243.81-$14.29M-$0.31N/A

In the previous week, Mainz Biomed had 4 more articles in the media than Talphera. MarketBeat recorded 4 mentions for Mainz Biomed and 0 mentions for Talphera. Mainz Biomed's average media sentiment score of 0.25 beat Talphera's score of 0.00 indicating that Mainz Biomed is being referred to more favorably in the media.

Company Overall Sentiment
Mainz Biomed Neutral
Talphera Neutral

Summary

Talphera beats Mainz Biomed on 8 of the 15 factors compared between the two stocks.

Get Mainz Biomed News Delivered to You Automatically

Sign up to receive the latest news and ratings for QUCY and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding QUCY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

QUCY vs. The Competition

Export
MetricMainz BiomedPharmaceutical Preparations IndustryManufacturing SectorNASDAQ Exchange
Market Cap$17.52M$968.20M$4.41B$12.40B
Dividend YieldN/A4.84%38.14%9.39%
P/E Ratio-0.031.5123.6324.12
Price / Sales31.63112.99139.8392.58
Price / CashN/A22.0530.1747.25
Price / Book16.648.6813.066.23
Net Income-$16.21M-$2.87M$120.21M$331.53M
7 Day Performance-7.54%-1.16%-1.11%-1.30%
1 Month Performance-33.81%1.85%-1.48%-1.40%
1 Year PerformanceN/A29.30%10.35%18.15%

Mainz Biomed Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
QUCY
Mainz Biomed
0.4589 of 5 stars		$1.17
+0.4%		N/AN/A$17.52M$540KN/A30
LFVN
Lifevantage
2.713 of 5 stars		$6.24
-0.2%		$5.00
-19.9%		-51.7%$78.75M$228.53M13.87260
HRTX
Heron Therapeutics
1.7763 of 5 stars		$0.41
-3.3%		$2.50
+503.3%		-75.1%$78.44M$150.71MN/A300
GANX
Gain Therapeutics
2.7752 of 5 stars		$1.80
-1.1%		$7.50
+316.7%		+2.8%$76.77M$50KN/A20
AIFC
ALT5 Sigma
0.1509 of 5 stars		$0.54
-2.6%		N/A-92.2%$75.81M$24.84MN/A170

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:QUCY) was last updated on 7/21/2026 by MarketBeat.com Staff.
From Our Partners
Elon’s new "tollbooth"
The SpaceX IPO was valued at $1.75 trillion. But one analyst says fighting over those shares may be the wrong ...
Weiss Ratings | Sponsoredtc pixel
Elon's new "super startup"
Adam O'Dell - the analyst who recommended Palantir before it became the top S&P 500 performer - has identified...
Banyan Hill Publishing | Sponsoredtc pixel